| 000 | 01374 a2200385 4500 | ||
|---|---|---|---|
| 005 | 20250517121745.0 | ||
| 264 | 0 | _c20170922 | |
| 008 | 201709s 0 0 eng d | ||
| 022 | _a1879-114X | ||
| 024 | 7 |
_a10.1016/j.clinthera.2016.09.012 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aYang, Li | |
| 245 | 0 | 0 |
_aEconomic Evaluation of Sevelamer versus Calcium-based Binders in Treating Hyperphosphatemia among Patients with End-stage Renal Disease in China. _h[electronic resource] |
| 260 |
_bClinical therapeutics _cNov 2016 |
||
| 300 |
_a2459-2467.e1 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article | ||
| 650 | 0 | 4 |
_aCalcium _xtherapeutic use |
| 650 | 0 | 4 |
_aChelating Agents _xtherapeutic use |
| 650 | 0 | 4 | _aChina |
| 650 | 0 | 4 | _aCost-Benefit Analysis |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHyperphosphatemia _xdrug therapy |
| 650 | 0 | 4 |
_aKidney Failure, Chronic _xtherapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aQuality-Adjusted Life Years |
| 650 | 0 | 4 |
_aSevelamer _xtherapeutic use |
| 650 | 0 | 4 | _aSurvival Analysis |
| 700 | 1 | _aChuen Tan, Seng | |
| 700 | 1 | _aChen, Can | |
| 700 | 1 | _aWang, Xingzhi | |
| 700 | 1 | _aLi, Xinya | |
| 700 | 1 | _aYang, Xiaoyan | |
| 773 | 0 |
_tClinical therapeutics _gvol. 38 _gno. 11 _gp. 2459-2467.e1 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.clinthera.2016.09.012 _zAvailable from publisher's website |
| 999 |
_c26524744 _d26524744 |
||